Capricor Therapeutics has delivered its sharpest weekly gain in months — up 13.3% to $28.38 — and for the first time since the bear campaign peaked, the short position is visibly retreating rather than merely pausing.
The directional shift in short interest is the headline development this week. After peaking at 25.1% of the free float in early June and then plateauing through mid-month, the position has now dropped to 24.1% — a 4.6% single-day reduction on June 18, the largest one-day cover since the build began. That brings the short score down fractionally to 75.6, still elevated but now moving the right way for bulls. The position remains substantial: 11 million shares short, 14.3 days to cover per the latest FINRA data, and a month-on-month increase of 4.5% that shows how aggressively bears accumulated through May. Bears are trimming at the margin, not fleeing. The important distinction is that previous reports documented a plateau; this week marks the first meaningful numeric decline.
The borrow market tells a surprisingly permissive story, which is what makes the covering noteworthy. Cost to borrow has nudged up 13% on the week to 0.56% — still rock-bottom for a name with 24% short interest. Availability has tightened from 235% to 190%, moving in the wrong direction for bears who want an easy exit, but still well within the range where new shorts can be established without difficulty. With 13.5 million shares still available to lend against 11 million currently borrowed, the lending pool is not under acute stress. The borrow picture is tight relative to a month ago — availability was above 350% in late May — but far from the squeeze conditions that would force a disorderly unwind. Options traders lean bullish: the put/call ratio has dropped to 0.39, nearly two standard deviations below its 20-day average on the call side, and well off the 0.45 readings from mid-May. The 52-week PCR range of 0.25 to 3.16 puts current positioning firmly in the call-heavy zone.
The institutional picture provides useful context for the week's price action. Suvretta Capital built a 3.8 million share position — good for roughly 6.6% of shares outstanding — as of the March quarter-end filing, adding 2.9 million shares in the period. Tang Capital similarly doubled its stake to 3.4 million shares. BlackRock and State Street have both added recently, with BlackRock reporting 570,000 new shares through May. These are not passive index flows; they are active managers increasing conviction during a period when the stock was under pressure. The counterweight is insider activity: the CFO and General Counsel both sold 25,000 shares apiece on May 1 at around $31.70, continuing a pattern of executive sales that stretches back through March. The insider net over 90 days runs to roughly $6.8 million in sales — modest at the individual level given the stock's market cap, but worth noting as the stock approaches those same execution prices from below.
The August 6 earnings date and the looming PDUFA window for deramiocel give the current positioning its particular charge. The stock's last quarterly print saw a 4.9% one-day drop followed by a 15.6% five-day slide — a pattern that explains why the short position built so aggressively during May and early June. But that was a result-driven sell-off; what bears are now weighing is a regulatory binary, not another quarterly miss. Close biotech peers moved broadly higher this week — AKBA added 19%, IMTX gained 7.9%, and DNTH rose 7.9% — suggesting sector tailwinds rather than CAPR-specific re-rating are partly behind the move.
The setup heading into Q3 narrows to one question: whether the short position continues its tentative retreat or restabilises above 24% as the PDUFA date approaches and the earnings print nears.
See the live data behind this article on ORTEX.
Open CAPR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
